Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Cited by 171

The DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.

Bortezomib and high-dose melphalan as conditioning regimen before autologous stem cell transplantation in patients with de novo multiple myeloma: a phase 2 study of the Intergroupe Francophone du Myélome (IFM)

Open access
Roussel, Murielle, Moreau, Philippe, Huynh, Anne, Mary, Jean-Yves, Danho, Clotaire, Caillot, Denis, Hulin, Cyrille, Fruchart, Christophe, Marit, Gérald, Pégourié, Brigitte, Lenain, Pascal, Araujo, Carla, Kolb, Brigitte, Randriamalala, Edouard, Royer, Bruno, Stoppa, Anne-Marie, Dib, Mammoun, Dorvaux, Véronique, Garderet, Laurent, Mathiot, Claire, Avet-Loiseau, Hervé, Harousseau, Jean-Luc, Attal, Michel, for the Intergroupe Francophone du Myélome (IFM) · 2010 · Blood

Abstract

Autologous stem cell transplantation (ASCT) is recommended for younger patients with newly diagnosed multiple myeloma. Achieving complete response (CR) or at least very good partial response (VGPR) is a major prognostic factor for survival with 20% to 30% of patients achieving CR after ASCT. Bortezomib has shown synergistic effects with melphalan and no prolonged hematologic toxicity. In this Intergroupe Francophone du Myélome (IFM) phase 2 study, 54 untreated patients were enrolled between July and December 2007 to receive bortezomib (1 mg/m2 × 4) and melphalan (200 mg/m2) as conditioning regimen (Bor-HDM). Overall, 70% of patients achieved at least VGPR, including 17 patients with CR (32%) after ASCT. No toxic deaths were observed. Bortezomib did not increase hematologic toxicity. Only 1 grade 3 to 4 peripheral neuropathy was reported. A matched control analysis was conducted comparing our cohort with patients from the IFM 2005-01 trial (HDM alone). Patients were matched for response to induction therapy and type of induction: CR was higher in the Bor-HDM group (35% vs 11%; P = .001), regardless of induction therapy. These results suggest that Bor-HDM is a safe and promising conditioning regimen. Randomized studies are needed to assess whether this conditioning regimen is superior to HDM alone. This trial was registered at www.clinicaltrials.gov as NCT00642395.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1182/blood-2009-06-229658

Cites

4 of 4 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 4 references

Cited by

See all 171

Metadata

Authors
Roussel, M., Moreau, P., Huynh, A., Mary, J.-Y., Danho, C., Caillot, D., Hulin, C., Fruchart, C., Marit, G., Pégourié, B., Lenain, P., Araujo, C., Kolb, B., Randriamalala, E., Royer, B., Stoppa, A.-M., Dib, M., Dorvaux, V., Garderet, L., Mathiot, C., Avet-Loiseau, H., Harousseau, J.-L., Attal, M., & (IFM), F. T. I. F. D. M.
Venue
Blood
Published
2010-01-07
Volume
115
Issue
1
Pages
32-37
ISSN
  • 0006-4971 (ISSN-L)
  • 1528-0020
OpenAlex
W2084542540
Cited by
171
References
4
FWCI
9.91
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Bortezomib and high-dose melphalan as conditioning regimen before autologous stem cell transplantation in patients with de novo multiple myeloma: a phase 2 study of the Intergroupe Francophone du Myélome (IFM). https://app.cochat.ai/papers/10.1182/blood-2009-06-229658
The paper
Roussel, M., Moreau, P., Huynh, A., Mary, J.-Y., Danho, C., Caillot, D., Hulin, C., Fruchart, C., Marit, G., Pégourié, B., Lenain, P., Araujo, C., Kolb, B., Randriamalala, E., Royer, B., Stoppa, A.-M., Dib, M., Dorvaux, V., Garderet, L., . . . (IFM), F. T. I. F. D. M. (2010). Bortezomib and high-dose melphalan as conditioning regimen before autologous stem cell transplantation in patients with de novo multiple myeloma: a phase 2 study of the Intergroupe Francophone du Myélome (IFM). Blood. https://doi.org/10.1182/blood-2009-06-229658

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.